Form 4: Zentalis Pharmaceuticals Director Enoch Kariuki Receives Significant Equity Grant

Zentalis Pharmaceuticals, Inc. Director Enoch Kariuki was granted 57,603 restricted stock units (RSUs) as part of the company's Non-Employee Director Compensation Program, aligning his interests with shareholders.

Summary

• Enoch Kariuki, a Director of Zentalis Pharmaceuticals, Inc. (ZNTL), acquired 57,603 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on June 17, 2025, with the RSUs granted at a price of $0.
• Following this transaction, Mr. Kariuki beneficially owns a total of 137,365 shares of common stock.
• These RSUs are contingent rights to receive one share of common stock each.
• The RSUs will vest on the earlier of June 17, 2026, or the date of the next annual meeting of the Issuer's stockholders, provided Mr. Kariuki continues his service on the Board of Directors through the vesting date.

Sentiment

Score: 7

Explanation: The sentiment is positive as the equity grant aligns the director's interests with shareholders, which is generally viewed favorably. It's a routine compensation event, not indicative of extraordinary news.

Positives

• The grant of Restricted Stock Units to Director Enoch Kariuki aligns his financial interests directly with the long-term performance and shareholder value of Zentalis Pharmaceuticals, Inc.
• This equity compensation is a standard practice for non-employee directors, indicating a structured approach to corporate governance and incentivization.

Risks

• The vesting of the 57,603 Restricted Stock Units is contingent upon Enoch Kariuki's continued service on the Issuer's Board of Directors through the vesting date (earlier of June 17, 2026, or the next annual meeting), meaning the shares are not immediately owned and could be forfeited if service ceases.

Future Outlook

The granted Restricted Stock Units are set to vest on the earlier of June 17, 2026, or the next annual meeting of stockholders, subject to the director's continued service, indicating a future milestone for the equity compensation.

Industry Context

The granting of Restricted Stock Units to non-employee directors is a common and widely accepted practice across the biotechnology and pharmaceutical industries. It serves to attract and retain experienced board members while aligning their incentives with the long-term success of the company and its shareholders.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a non-employee director is a standard form of equity compensation in the biotechnology and pharmaceutical sectors, consistent with practices observed at comparable companies.
• While the specific value and number of RSUs granted vary by company size, stage, and compensation philosophy, this type of equity award is a common mechanism to incentivize long-term commitment and align director interests with shareholder value.
• Specific comparable companies, projects, or results are not detailed within this Form 4 filing, as it focuses solely on the individual's transaction.

Corporate Governance

Related Party Transactions

• The grant of 57,603 Restricted Stock Units to Enoch Kariuki, a Director of Zentalis Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to more shareholder-centric decision-making and long-term value creation.
• Employees: No direct impact on employees is indicated by this specific filing.
• Customers: No direct impact on customers is indicated by this specific filing.
• Suppliers: No direct impact on suppliers is indicated by this specific filing.
• Creditors: No direct impact on creditors is indicated by this specific filing.

Next Steps

• The Restricted Stock Units are expected to vest on the earlier of June 17, 2026, or the next annual meeting of Zentalis Pharmaceuticals' stockholders, contingent on Director Kariuki's continued service.

Key Dates

Keywords

Zentalis Pharmaceuticals, ZNTL, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction, Enoch Kariuki, Corporate Governance